Our findings, which we have subsequently validated in in vitro studies of human islets and beta cells (unpublished data), therefore highlight Hpse inhibitors as a new class of therapeutic that can potentially be used to prevent T1D progression in humans. This evidence concerns the gene HPSE and type 1 diabetes mellitus.